KRAS amplification was implicated as the mechanism of resistance from crizotinib treatment in MET exon 14 mutant-NSCLC in a study using patient tumor-derived cells and xenografts, which was effectively targeted by dual MET/PI3K inhibition (42). The gene discussed is MET; the disease is neoplasm.